AstraZeneca Pharma India Limited — Important, 22-03-2025: Updates

The company has received a draft Order Giving Effect to the order of the Hon’ble Income-tax Appellate Tribunal related to the assessment year 2014-15. This order confirms that major adjustments regarding transfer pricing and corporate tax issues have been deleted. The expected financial implication from this development is a tax relief of approximately Rs. 35.22 crores (Cr), excluding interest. This outcome is significant as it may positively impact cash flows and enhance the company's fiscal position. Investors should watch closely for further updates, considering the potential benefits this tax relief could bring to the company's financial trajectory.